Drug developer Generate Biomedicines raises $400 million in US IPO
ReutersFeb 27, 2026 1:09 AM
Feb 26 (Reuters) - Drug developer Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares at $16 each.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
How Doomed is Salesforce (CRM)?
Declaring that SaaS is dead has become a popular narrative among some investors and commentators, especially as artificial intelligence reshapes enterprise software. However, this view is overly simplistic and lazyTradingKey
2 hours ago
Tesla Steps Up China Market Promotions; Can EV Business Bottom Out and Rebound?
TradingKey - On February 26 local time, Tesla (TSLA) China announced that for orders placed by March 31, select models will be eligible for 7-year ultra-low interest and 5-year zero-interest financing plans, as well as insurance subsidies.TradingKey
20 hours ago
Nvidia Q4 Earnings: Market Fears Competition, but NVDA Moat is Beyond CUDA
All eyes are on Nvidia this week, as the company reports its 2026Q4 earnings.TradingKey
Wed, Feb 25
Will Bank of England Still Cut Rates in 2026? Falling Inflation Favors Loose Monetary Policy, Pound Exchange Rate May Struggle to Sustain Strength.
TradingKey - The outlook for the British Pound in 2026 is undoubtedly one of the most significant focal points for investors in the FX market. Following a structural shift in 2025 characterized by a "low start and high finish," GBP/USD successfully broke out of its two-year trading range and stabilized near 1.35 at year-end, laying the foundation for its performance in 2026.TradingKey
Fri, Feb 20
Intel’s Foundry Business Faces a Turning Point in 2026 — Earnings Could Be the Latest Catalyst
TradingKey - Amid a wave of “Sell America” sentiment sweeping across U.S. tech stocks, Intel (INTC) has stood out, bucking the broader market downturn. The stock has risen nearly 140% over the past year. For investors, the next potential catalyst lies just ahead—Intel’s upcoming earnings report.TradingKey
Thu, Jan 22
